Metavia Inc (MTVA) Stock Price, Quote & News

Company Profile

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomod...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 702 9600

Website: www.metaviatx.com

Address:

545 Concord Avenue, Suite 210, Cambridge, United States

BioRich Oct. 16 at 10:57 PM

$ALT @Wolly99 @Turribull @Designed2Gain Our resident 80%er sharing exciting information about another company's AASLD presentation. Great news for them. I've also highlighted the cT1 focused information from MDGL and others. Take a look at $IVA's AASLD presentations if you want to get super excited about the role of NITs moving forward. Sad to see ALTers pumping other companies/drugs unknowingly while ALT continues to screw them. It doesn't even look like $ALT is invited anymore. That Fibrosis FAILURE continues to haunt them. Well, that and questionable data. Cheers $MDGL, $VKTX, $MTVA for your solid future in MASH/Fibrosis. $ALT, maybe you can hand out free samples of Dose at the door. Cheers!

0 · Reply

SPYmyQQQ Oct. 14 at 11:03 AM

🚀 New Signal ✅ 💊 $MTVA 🗓️ Oct 14, 2025 💵 Entry: $0.9905 🎯 Target (Opt.): $1.17 (+18.16%) 👉 FREE TRIAL! Check bio.

0 · Reply

Basko151 Oct. 9 at 12:01 PM

$MTVA the slow grind higher….any news and this thing will pop $5

0 · Reply

SPYmyQQQ Oct. 7 at 1:25 AM

🎯 Target Hit 🏁 📨 From Sep 30, 2025 💊 $MTVA 💵 Entry: $0.9650 ✅ Exit: $1.1477 💰 P/L: +18.93% 👉 FREE TRIAL! spymyqqq/join/

0 · Reply

warrants_Moon Oct. 6 at 2:53 PM

$VKTX watch $MTVA early stages in GLP/mash space. Top line results expected in 4th quarter

0 · Reply

PivotHawk Oct. 5 at 12:54 PM

$MTVA Media broadcasting challenges. Advertising market weakness. Chart shows distribution pattern. Avoid.

0 · Reply

Chinna11 Oct. 1 at 10:02 PM

$MTVA It's about to gain some momentum and keep an eye on it !

0 · Reply

Basko151 Oct. 1 at 3:42 PM

$MTVA LFG!!

0 · Reply

Kertzi Oct. 1 at 4:27 AM

$MTVA Insider trading continues and no one cares, as we see e.g. in the Mullen/Bollinger case. The US Nasdaq and the SEC are enabling and allowing scams and criminal activities.

1 · Reply

SPYmyQQQ Sep. 30 at 9:02 AM

🚀 New Signal ✅ 💊 $MTVA 🗓️ Sep 30, 2025 💵 Entry: $0.9650 🎯 Target (Opt.): $1.15 (+18.93%) 👉 Check bio for full access

0 · Reply

MetaVia Announces Poster Presentations on DA-1726 at ObesityWeek® 2025

Oct 14, 2025, 8:31 AM EDT - 11 days ago

MetaVia to Present at the H.C. Wainwright Liver Disease Virtual Conference

Aug 26, 2025, 8:31 AM EDT - 2 months ago

MetaVia to Present at Upcoming Investor and Industry Conferences

Aug 7, 2025, 8:31 AM EDT - 2 months ago

MetaVia Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 6, 2025, 8:31 AM EDT - 2 months ago

MetaVia Extends 48 mg MAD Portion of Its Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient

Aug 4, 2025, 8:31 AM EDT - 2 months ago

MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241

Jul 9, 2025, 8:31 AM EDT - 3 months ago

MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated Dose

Jun 21, 2025, 9:00 AM EDT - 4 months ago

MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA's 85th Scientific Session

Jun 10, 2025, 8:31 AM EDT - 4 months ago

MetaVia to Present at the Life Sciences Virtual Investor Forum June 12th

Jun 4, 2025, 8:31 AM EDT - 5 months ago

MetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific Sessions

May 14, 2025, 4:05 PM EDT - 5 months ago

MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 9, 2025, 8:01 AM EDT - 6 months ago

MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

May 7, 2025, 2:00 AM EDT - 6 months ago

MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025

Apr 23, 2025, 8:31 AM EDT - 6 months ago

MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025

Apr 22, 2025, 8:31 AM EDT - 6 months ago

MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential

Apr 15, 2025, 7:01 AM EDT - 6 months ago

MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability

Mar 20, 2025, 7:31 AM EDT - 7 months ago

MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update

Jan 10, 2025, 8:05 AM EST - 10 months ago

MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference

Nov 18, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases

Nov 13, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals to Participate in Investor Conferences in November

Nov 7, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 4, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Oct 1, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals to Participate in Investor Conferences in October

Sep 30, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Sep 3, 2024, 8:01 AM EDT - 1 year ago

NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aug 14, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 13, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Aug 6, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity

Jul 30, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01

Jul 11, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July

Jun 26, 2024, 9:06 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Jun 25, 2024, 5:08 PM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 24, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 22, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models

May 22, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone

May 9, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 30, 2024, 8:01 AM EDT - 1 year ago

NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June

Apr 17, 2024, 8:05 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Apr 1, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Mar 28, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update

Mar 13, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Mar 4, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer

Feb 29, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Feb 12, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference

Feb 1, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

Jan 18, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Jan 9, 2024, 8:30 AM EST - 1 year ago

NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement

Jan 2, 2024, 8:01 AM EST - 1 year ago

NeuroBo to Participate in Industry and Investor Conferences in January

Dec 28, 2023, 8:45 AM EST - 1 year ago

NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

Dec 19, 2023, 8:43 AM EST - 2 years ago

NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Split

BioRich Oct. 16 at 10:57 PM

0 · Reply

SPYmyQQQ Oct. 14 at 11:03 AM

🚀 New Signal ✅ 💊 $MTVA 🗓️ Oct 14, 2025 💵 Entry: $0.9905 🎯 Target (Opt.): $1.17 (+18.16%) 👉 FREE TRIAL! Check bio.

0 · Reply

Basko151 Oct. 9 at 12:01 PM

$MTVA the slow grind higher….any news and this thing will pop $5

0 · Reply

SPYmyQQQ Oct. 7 at 1:25 AM

🎯 Target Hit 🏁 📨 From Sep 30, 2025 💊 $MTVA 💵 Entry: $0.9650 ✅ Exit: $1.1477 💰 P/L: +18.93% 👉 FREE TRIAL! spymyqqq/join/

0 · Reply

warrants_Moon Oct. 6 at 2:53 PM

$VKTX watch $MTVA early stages in GLP/mash space. Top line results expected in 4th quarter

0 · Reply

PivotHawk Oct. 5 at 12:54 PM

$MTVA Media broadcasting challenges. Advertising market weakness. Chart shows distribution pattern. Avoid.

0 · Reply

Chinna11 Oct. 1 at 10:02 PM

$MTVA It's about to gain some momentum and keep an eye on it !

0 · Reply

Basko151 Oct. 1 at 3:42 PM

$MTVA LFG!!

0 · Reply

Kertzi Oct. 1 at 4:27 AM

$MTVA Insider trading continues and no one cares, as we see e.g. in the Mullen/Bollinger case. The US Nasdaq and the SEC are enabling and allowing scams and criminal activities.

1 · Reply

SPYmyQQQ Sep. 30 at 9:02 AM

🚀 New Signal ✅ 💊 $MTVA 🗓️ Sep 30, 2025 💵 Entry: $0.9650 🎯 Target (Opt.): $1.15 (+18.93%) 👉 Check bio for full access

0 · Reply

RadioIsotope25 Sep. 25 at 3:04 AM

$RADX https://x.com/teamradiopharm/status/1970689873301668003?s=46 $MTVA

0 · Reply

BULLISH1975 Sep. 24 at 4:13 PM

$ICU $MTVA $CLNN $KZIA looking for a micro cap with phase III interim due plus much more in coming days!!! see dd below! i think you will be glad you took a close look!!!! good luck

2 · Reply

Basko151 Sep. 24 at 3:06 PM

$MTVA Am I the only one Buying???

0 · Reply

Chinna11 Sep. 22 at 10:20 AM

$MTVA push something here

0 · Reply

peepthestamp Sep. 21 at 3:50 PM

$SKYQ $PT $VEEA $ALXO $MTVA

0 · Reply

Basko151 Sep. 19 at 5:29 PM

$MTVA I see a bull flag on the 1hr, hopefully we get confirmation into the weekend!!

2 · Reply

smoketuna Sep. 19 at 7:52 AM

$MTVA 85% with 🎯 TunaSignal.ai score! while price $1.04 - Catch the Big Movers Before They Break Out - Powered by AI

0 · Reply

TraderJay85 Sep. 18 at 9:37 PM

All these are setting up and should be on close watch. $MTVA $ANGX $NAOV $GORV $QNRX

1 · Reply

Kertzi Sep. 18 at 5:17 PM

$MTVA When $23? @ZacksSCR

1 · Reply

TraderRapp Sep. 18 at 3:51 PM

$MTVA where did all that 73Million share volume go the other day? literally all one day then nothing.

1 · Reply

Chinna11 Sep. 18 at 3:12 PM

$MTVA Damm

0 · Reply

Chinna11 Sep. 18 at 3:13 AM

$MTVA More likely a Bad News but cash burn rate is a good part here ! https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mtva/metavia/news/were-keeping-an-eye-on-metavias-nasdaqmtva-cash-burn-rate?utm_medium=article&utm_source=robinhood

0 · Reply

Market Cap	23.26M
Revenue (ttm)	0.00
Net Income (ttm)	-27.59M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	22,200
Avg Vol	2,068,942
Day's Range	N/A - N/A
Shares Out	24.20M
Stochastic %K	38%
Beta	0.37
Analysts	Strong Sell
Price Target	$13.75